DEF 14A: China Pharma Seeks Reverse Split to Avoid Delisting

China Pharma Holdings, Inc. will hold its Annual Meeting to vote on a reverse stock split, an independent director election, and an amendment to its long-term incentive plan.

Summary

• The Annual Meeting of Stockholders for the fiscal year ended December 31, 2024, will be held on December 30, 2025.
• Stockholders will vote on the election of three independent directors.
• A proposal to authorize a reverse stock split of outstanding common stock at a ratio of up to 1:20 will be considered to maintain compliance with NYSE American listing standards.
• The company has previously completed two reverse stock splits: 1-for-5 on March 6, 2024, and 1-for-10 on April 15, 2025.
• An amendment to the Amended and Restated 2010 Long-Term Incentive Plan will be voted on, increasing the number of shares reserved thereunder by 500,000, from 69,600 to 569,600 shares.
• The Board of Directors recommends a vote FOR all three proposals.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the necessity of a reverse stock split to avoid delisting, indicating poor underlying stock performance and value erosion. The history of previous reverse splits reinforces this negative outlook. While the incentive plan aims to retain talent, the significant increase in shares could be dilutive. The substantial related party transactions with the CEO also raise governance concerns.

Positives

• The Board of Directors recommends a vote FOR the election of the three independent director nominees, indicating continuity in governance.
• The company is in compliance with NYSE American rule 802(c) regarding board meetings.
• A code of business conduct and ethics is in place for all directors and employees, promoting ethical conduct and compliance.

Negatives

• The necessity of a reverse stock split at a ratio of up to 1:20 indicates a sustained low stock price and a risk of non-compliance with NYSE American listing standards, potentially leading to delisting.
• The company has a history of stock price volatility and has already completed two reverse stock splits (1-for-5 on March 6, 2024, and 1-for-10 on April 15, 2025) within the last two years.
• Significant related party transactions exist, including advances from Chairperson, CEO, and Interim CFO Ms. Zhilin Li totaling $1,144,985 as of December 31, 2024, and a loan of $738,379 at 4.35% interest due July 9, 2025.
• Compensation payable to Ms. Li included in Other payables totaled $1,559,506 as of December 31, 2024.

Risks

• Failure to approve the reverse stock split could result in the inability to maintain the listing of common stock on NYSE American, adversely affecting liquidity and marketability.
• There is no assurance that the reverse stock split will achieve the desired increase in market price or that any increased price will be maintained for any period of time.
• The reverse stock split may be viewed negatively by investors, potentially adversely impacting the market price of common stock.
• The liquidity of common stock could be adversely affected by the reduced number of shares outstanding after a reverse stock split.
• Even if the reverse stock split is successful in raising the share price, there is a risk that the company may not satisfy other NYSE American continued listing criteria.
• The issuance of additional shares under the Amended and Restated 2010 Long-Term Incentive Plan could lead to dilution for existing stockholders.
• Tax consequences related to incentive stock options, non-qualified stock options, restricted shares, and performance units under the Plan may vary for participants.
• Limits on deductions for executive compensation under Section 162(m) of the Code may apply, and excess parachute payments in a change of control could be subject to a 20% excise tax and be non-deductible by the company.

Future Outlook

The company aims to maintain its listing on NYSE American by potentially implementing a reverse stock split. It also seeks to enhance its ability to attract and retain employees, officers, directors, and consultants by significantly increasing the shares available under its long-term incentive plan, aligning participant interests with stockholders.

Management Comments

• Zhilin Li, Chairman of the Board, stated, "At the Annual Meeting we will report on important activities and accomplishments of our company and review our financial performance and business operations."
• The Board of Directors believes the combined role of Chief Executive Officer and Chairman is most suitable as Ms. Li is most familiar with the business and industry, effectively identifying strategic priorities.
• The Board of Directors recommends a vote FOR the election of each independent director nominee, FOR the authorization of the reverse stock split, and FOR the approval of Amendment No.3 to the Amended and Restated 2010 Long-Term Incentive Plan.

Industry Context

This announcement reflects a common challenge for companies with low stock prices, particularly those listed on exchanges like NYSE American, which have minimum price requirements. The need for a reverse stock split indicates that the company's stock performance has lagged, potentially due to company-specific factors or broader market sentiment towards smaller-cap or China-based pharmaceutical companies. The increase in the incentive plan pool is a standard practice to attract and retain talent, but its magnitude should be viewed in the context of the company's overall performance and market capitalization.

Comparison to Industry Standards

• The proposed reverse stock split at a ratio of up to 1:20, following two previous splits (1:5 and 1:10), suggests a persistent struggle to maintain a viable stock price, which is generally below the performance of stable, well-capitalized pharmaceutical companies.
• The significant related party transactions with the CEO, including substantial borrowings and loans, could be viewed as a corporate governance concern compared to industry best practices that emphasize arm's-length dealings to protect minority shareholder interests.
• The increase in the long-term incentive plan share pool by 500,000 shares, while a common tool for talent retention, should be assessed against the company's market capitalization and peer group dilution rates to determine if it is within reasonable industry benchmarks, especially given the company's performance challenges.

Corporate Governance

Related Party Transactions

• The company has received advances from its Chairperson, Chief Executive Officer, and Interim Chief Financial Officer, Ms. Zhilin Li. Total amounts owed were $1,144,985 as of December 31, 2024, and $1,133,809 as of December 31, 2023, recorded as Borrowings from related parties.
• On July 8, 2019, the company entered into a loan agreement with Ms. Li for RMB 4,770,000 (approximately $738,379). The loan bears interest at 4.35% and its due date has been extended annually, currently set for July 9, 2025.
• Total interest expense related to this loan was $27,353 for the year ended December 31, 2024, and $27,644 for the year ended December 31, 2023.
• Compensation payable to Ms. Li is included in Other payables, totaling $1,559,506 as of December 31, 2024, and $1,243,506 as of December 31, 2023.

Stakeholder Impact

• Shareholders: Will be impacted by the potential reverse stock split, which aims to maintain listing but carries risks of further price volatility and liquidity issues. The increase in the incentive plan shares could lead to dilution. Voting on key corporate actions is crucial.
• Employees and Directors: Will benefit from the expanded 2010 Long-Term Incentive Plan, which aims to attract and retain talent through stock-based compensation.
• NYSE American: The company's actions, particularly the reverse stock split, are directly aimed at complying with its listing standards to avoid delisting.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on December 30, 2025.
• If approved, the Board of Directors will have the discretion to determine the final ratio and effective time for the reverse stock split.
• The Amended and Restated 2010 Long-Term Incentive Plan, if approved, will have an increased share reserve for future awards.

Key Dates

Recommendation

The company's repeated need for reverse stock splits (three in total, including the proposed one) to maintain its NYSE American listing signals severe and persistent issues with its stock price and underlying business performance. This history suggests that previous attempts to address the low stock price have not been sustainably effective. Furthermore, the significant related party transactions with the CEO, including substantial loans and payables, raise red flags regarding corporate governance and potential conflicts of interest. While the expansion of the incentive plan aims to retain talent, it also introduces potential dilution for existing shareholders without clear evidence of improved operational performance. For a seasoned investor, these factors collectively point to a high-risk investment with a strong likelihood of continued underperformance and potential delisting, making a 'sell' recommendation appropriate.

Keywords

China Pharma Holdings, CPHI, SEC filing, DEF 14A, proxy statement, reverse stock split, stock options, incentive plan, corporate governance, NYSE American, delisting risk, executive compensation, related party transactions, independent directors